L'Hospitalet de Llobregat-Barcelona, Spain Clinical Trials

A listing of L'Hospitalet de Llobregat-Barcelona, Spain clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 134 clinical trials
featured
A Study to Evaluate the Safety Tolerability and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for …

dyskinesia
Hospital Clinic de Barcelona
 (2.4 away) Contact site
  • 250 views
  • 25 May, 2021
  • +13 other locations
featured
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)  

cancer
measurable disease
bendamustine
rituximab
refractory follicular lymphoma
Parc de Salut MAR - Hospital del Mar
 (3.1 away) Contact site
  • 560 views
  • 23 Nov, 2020
  • +11 other locations
featured
A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab,or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.  

lymphoma
b-cell lymphoma
lymphomas
HOSPITAL CLINIC DE BARCELONA
 (2.4 away) Contact site
  • 72 views
  • 14 Dec, 2020
  • +20 other locations
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic HER2-positive breast cancer

Hospital Cl nic i Provincial de Barcelona
 (2.4 away) Contact site
  • 5 views
  • 25 May, 2021
  • +33 other locations
End-stage Renal Disease (ESRD) Pilot Study

The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Approximately 40, with up to 60 study patients will take part in the study.

renal failure
nephropathy
hemodiafiltration
Ciutat Sanit ria i Universit ria de Bellvitge
 (1.3 away) Contact site
  • 66 views
  • 02 Jun, 2021
  • +39 other locations
Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors

The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with budigalimab. The study will consist of 2 phases: dose escalation …

Hospital Clinic de Barcelona /ID# 221106
 (2.4 away) Contact site
  • 17 views
  • 31 May, 2021
  • +37 other locations
A Study to Evaluate the Reactogenicity Safety Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.

A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed subjects under nucleo(s)tide treatment.

hepatitis b core antibody
bilateral oophorectomy
fibroscan
cirrhosis
hepatitis b e antigen
GSK Investigational Site
 (1.3 away) Contact site
  • 16 views
  • 05 Jun, 2021
  • +33 other locations
Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer

To evaluate the safety and tolerability of AMG 199 in adult subjects with MUC17-positive gastric and gastroesophageal junction cancer and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Research Site
 (4.3 away) Contact site
  • 7 views
  • 13 Jun, 2021
  • +38 other locations
Investigating Safety Tolerability Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.

Research Site
 (1.5 away) Contact site
  • 16 views
  • 02 Jun, 2021
  • +19 other locations
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab …

EGFR
cancer treatment
tyrosine
epidermal growth factor
cancer chemotherapy
Hosp. Univ. Quiron Dexeus
 (1.1 away) Contact site
  • 5 views
  • 15 Jun, 2021
  • +86 other locations